Immunomarker Expression Clarified for Thoracic Tumors
By LabMedica International staff writers Posted on 03 Jan 2016 |
Comprehensive morphological and immunohistochemical subtyping of tumors is of growing importance for therapy selection and propelled the concept of a tumor-specific, individualized treatment.
Thoracic pathologists are frequently faced with tissue specimens from intrathoracic/mediastinal tumors and specifically the differentiation between thymic and pulmonary squamous cell carcinomas (SqCC) can be challenging. For non-small-cell lung cancer (NSCLC) the current classification therefore has been extended by the concept of immunophenotyping from biopsies to resection specimens.
Scientists at Heidelberg University (Germany) identified a cohort of 1,465 patients for whom formalin-fixed paraffin-embedded specimens of NSCLC were available. Prior to tissue microarray (TMA) construction, a hematoxylin and eosin (H&E)-stained slide of each block was analyzed in order to select representative tumor-containing regions.
A TMA machine (AlphaMetrix Biotech; Rödermark, Germany) was used to extract a tandem 1.0 mm cylindrical core sample from each tissue donor block. Immunohistochemistry (IHC) was performed with commercially available antibodies and TMA slides were deparaffinized and pretreated with antigen retrieval buffer. Subsequent steps were performed on a BenchMark Ultra, immunostaining instrument (Ventana, Tucson, AZ, USA). The TMA resection specimens were stained with antibodies against CD117 and CD5.
CD117 was positive in 145 out of 1,457 evaluable cases (9.9%) and CD5 was positive in 133 out of 1,427 evaluable cases (9.3%). Coexpression of CD117 and CD5 was seen in 28 cases (1.9%). Among the 145 cases that were positive for CD117, 97 (66.8%) were adenocarcinomas (ADC), 34 (23.4%) were SqCC, 5 (3.4%) were adenosquamous carcinomas (ADSqCC), 8 (5.5%) were large cell carcinomas (LC), and one (0.6%) was a pleomorphic carcinoma (PC). In the CD5 positive group consisting of 133 cases, 123 (92.4%) were ADC, four (3.0%) were ADSqCC, three (2.2%) LC and three (2.2%) were PC. None of the 586 SqCC showed expression of CD5.
The authors concluded that a substantial subset of NSCLC exhibit positivity of CD117 and CD5. Since CD5 expression was not observed in pulmonary SqCC, but is expressed in the majority of thymic squamous cell carcinomas, the application of this immunomarker is a valuable tool in the differential diagnosis of thoracic neoplasms. The study was published on December 8, 2015, in the journal Diagnostic Pathology.
Related Links:
Heidelberg University
AlphaMetrix Biotech
Ventana
Thoracic pathologists are frequently faced with tissue specimens from intrathoracic/mediastinal tumors and specifically the differentiation between thymic and pulmonary squamous cell carcinomas (SqCC) can be challenging. For non-small-cell lung cancer (NSCLC) the current classification therefore has been extended by the concept of immunophenotyping from biopsies to resection specimens.
Scientists at Heidelberg University (Germany) identified a cohort of 1,465 patients for whom formalin-fixed paraffin-embedded specimens of NSCLC were available. Prior to tissue microarray (TMA) construction, a hematoxylin and eosin (H&E)-stained slide of each block was analyzed in order to select representative tumor-containing regions.
A TMA machine (AlphaMetrix Biotech; Rödermark, Germany) was used to extract a tandem 1.0 mm cylindrical core sample from each tissue donor block. Immunohistochemistry (IHC) was performed with commercially available antibodies and TMA slides were deparaffinized and pretreated with antigen retrieval buffer. Subsequent steps were performed on a BenchMark Ultra, immunostaining instrument (Ventana, Tucson, AZ, USA). The TMA resection specimens were stained with antibodies against CD117 and CD5.
CD117 was positive in 145 out of 1,457 evaluable cases (9.9%) and CD5 was positive in 133 out of 1,427 evaluable cases (9.3%). Coexpression of CD117 and CD5 was seen in 28 cases (1.9%). Among the 145 cases that were positive for CD117, 97 (66.8%) were adenocarcinomas (ADC), 34 (23.4%) were SqCC, 5 (3.4%) were adenosquamous carcinomas (ADSqCC), 8 (5.5%) were large cell carcinomas (LC), and one (0.6%) was a pleomorphic carcinoma (PC). In the CD5 positive group consisting of 133 cases, 123 (92.4%) were ADC, four (3.0%) were ADSqCC, three (2.2%) LC and three (2.2%) were PC. None of the 586 SqCC showed expression of CD5.
The authors concluded that a substantial subset of NSCLC exhibit positivity of CD117 and CD5. Since CD5 expression was not observed in pulmonary SqCC, but is expressed in the majority of thymic squamous cell carcinomas, the application of this immunomarker is a valuable tool in the differential diagnosis of thoracic neoplasms. The study was published on December 8, 2015, in the journal Diagnostic Pathology.
Related Links:
Heidelberg University
AlphaMetrix Biotech
Ventana
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Pathology News
- AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
- HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities